| JaLCDOI | 10.18926/AMO/30737 |
|---|---|
| FullText URL | fulltext.pdf |
| Author | Suzaki, Noriyuki| Hiraki, Akio| Takigawa, Nagio| Ueoka, Hiroshi| Tanimoto, Yasushi| Kozuki, Toshiyuki| Tabata, Masahiro| Kanehiro, Arihiko| Kiura, Katsuyuki| Tanimoto, Mitsune| |
| Abstract | A 71-year-old Japanese man with adenocarcinoma of the lung developed interstitial pneumonia after treatment with paclitaxel. The patient had acute chills and fever on the fourth day after the second exposure to paclitaxel, rapidly got worse despite empiric therapies, and developed prolonged respiratory failure requiring mechanical ventilation. Four months later, he died of respiratory failure due to progression of both interstitial pneumonia and lung cancer. This is the first case developing fatal paclitaxel-induced pulmonary toxicity to date. Interstitial pneumonia should be considered one of the possible life-threatening complications during treatment with paclitaxel. |
| Keywords | paclitaxel adverse effect lung cancer interstitial pneumonia |
| Amo Type | Article |
| Published Date | 2006-10 |
| Publication Title | Acta Medica Okayama |
| Volume | volume60 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 295 |
| End Page | 298 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 17072376 |
| Web of Science KeyUT | 000241509000006 |
| JaLCDOI | 10.18926/AMO/48564 |
|---|---|
| FullText URL | 66_3_245.pdf |
| Author | Okada, Toshiaki| Takigawa, Nagio| Kishino, Daizo| Katayama, Hideki| Kuyama, Shouichi| Sato, Ken| Mimoto, Junko| Ueoka, Hiroshi| Tanimoto, Mitsune| Kiura, Katsuyuki| |
| Abstract | Cisplatin is used to treat lung cancer;however, it is also a known carcinogen. Cyclooxygenase-2 (COX-2) inhibitors have been shown to prevent carcinogen-induced experimental tumors. We investigated the effect of a COX-2 inhibitor, celecoxib, on cisplatin-induced lung tumors. One hundred twenty 4-week-old A/J mice were divided into 6 groups:group 1, no treatment;group 2, low-dose celecoxib (150mg/kg);group 3, high-dose celecoxib (1,500mg/kg);group 4, cisplatin alone;group 5, cisplatin plus low-dose celecoxib;and group 6, cisplatin plus high-dose celecoxib. Mice in groups 4-6 were administered cisplatin (1.62mg/kg, i.p.) once a week for 10 weeks between 7 and 16 weeks of age. All mice were sacrificed at week 30. Tumor incidence was 15.8% in group 1, 25% in group 2, 26.3% in group 3, 60% in group 4, 50% in group 5, and 50% in group 6. Tumor multiplicity was 0.2, 0.3, 0.3, 1.3, 1.0, and 0.6 in groups 1-6, respectively. Tumor multiplicity in the cisplatin-treated mice was reduced by celecoxib treatment in a dose-dependent manner (p＜0.05, group 4 vs. group 6). Celecoxib significantly reduced COX-2 expression in cisplatin-induced tumors (p＜0.01, group 4 vs. group 6). |
| Keywords | cisplatin non-small cell lung cancer celecoxib cyclooxygenase-2 chemoprevention |
| Amo Type | Original Article |
| Published Date | 2012-06 |
| Publication Title | Acta Medica Okayama |
| Volume | volume66 |
| Issue | issue3 |
| Publisher | Okayama University Medical School |
| Start Page | 245 |
| End Page | 251 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| Copyright Holders | CopyrightⒸ 2012 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 22729105 |
| Web of Science KeyUT | 000305669700008 |
| FullText URL | fulltext.pdf |
|---|---|
| Author | Sugiura, Hiroyuki| Nishimori, Hisakazu| Nishii, Kazuya| Toji, Tomohiro| Fujii, Keiko| Fujii, Nobuharu| Matsuoka, Ken-ichi| Nakata, Koh| Kiura, Katsuyuki| Maeda, Yoshinobu| |
| Keywords | pulmonary alveolar proteinosis primary myelofibrosis autopsy ruxolitinib |
| Published Date | 2020-08-15 |
| Publication Title | Internal Medicine |
| Volume | volume59 |
| Issue | issue16 |
| Start Page | 2023 |
| End Page | 2028 |
| ISSN | 0918-2918 |
| NCID | AA10827774 |
| Content Type | Journal Article |
| language | 英語 |
| OAI-PMH Set | 岡山大学 |
| Copyright Holders | © 2020 by The Japanese Society of Internal Medicine |
| File Version | publisher |
| PubMed ID | 32448830 |
| DOI | 10.2169/internalmedicine.4082-19 |
| Web of Science KeyUT | 000563078400014 |
| Related Url | isVersionOf https://doi.org/10.2169/internalmedicine.4082-19 |
| FullText URL | fulltext.pdf |
|---|---|
| Author | Katsui, Kuniaki| Ogata, Takeshi| Sugiyama, Soichi| Yoshio, Kotaro| Kuroda, Masahiro| Hiraki, Takao| Kiura, Katsuyuki| Maeda, Yoshinobu| Toyooka, Shinichi| Kanazawa, Susumu| |
| Published Date | 2021-06-04 |
| Publication Title | scientific reports |
| Volume | volume11 |
| Issue | issue1 |
| Publisher | Nature Research |
| Start Page | 11882 |
| ISSN | 2045-2322 |
| Content Type | Journal Article |
| language | 英語 |
| OAI-PMH Set | 岡山大学 |
| Copyright Holders | © The Author(s) 2021 |
| File Version | publisher |
| PubMed ID | 34088965 |
| DOI | 10.1038/s41598-021-91449-z |
| Web of Science KeyUT | 000678611200010 |
| Related Url | isVersionOf https://doi.org/10.1038/s41598-021-91449-z |
| JaLCDOI | 10.18926/AMO/30751 |
|---|---|
| FullText URL | fulltext.pdf |
| Author | Kitajima, Takuji| Nishii, Kenji| Ueoka, Hiroshi| Shibayama, Takuo| Gemba, Kenichi| Kodani, Tsuyoshi| Kiura, Katsuyuki| Tabata, Masahiro| Hotta, Katsuyuki| Tanimoto, Mitsune| Sobue, Tomotaka| |
| Abstract | <p>To evaluate recent improvements in lung cancer screening, we compared the results of recently conducted lung cancer screening with those of a previous screening. This study compared the survival of lung cancer patients detected by lung cancer screening conducted between 1976 and 1984 (early period) with that conducted between 1989 and 1997 (late period). Two hundred seventy-six patients with lung cancer were detected in the early period and 541 patients with lung cancer were detected in the late period. The median survival time (late : 49.8 vs. early : 27.8 months) and the 5-year survival rate (late : 47.8 vs. early : 34.8%) of the patients with lung cancer detected in the late period were significantly better than those in the early period (p = 0.0054). Among patients undergoing resection, the proportion of pathological stage I patients in the late period was significantly higher than that in the early period (late : 60.8 vs. early : 54.9%, p = 0.005). Multivariate analysis showed that the screening time period was a significant prognostic factor (hazard ratio = 0.685, 95% confidence interval : 0.563-0.832, p = 0.0002). These results were consistent with the findings of case-control studies of lung cancer screening programs in the late period recently conducted in Japan, which also showed a greater efficacy for screening than for previous case-control studies in the early period.</p> |
| Keywords | lung cancer screening survival lung cancer mortality |
| Amo Type | Article |
| Published Date | 2006-06 |
| Publication Title | Acta Medica Okayama |
| Volume | volume60 |
| Issue | issue3 |
| Publisher | Okayama University Medical School |
| Start Page | 173 |
| End Page | 179 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 16838046 |
| Web of Science KeyUT | 000238503600005 |
| JaLCDOI | 10.18926/AMO/60802 |
|---|---|
| FullText URL | 74_5_423.pdf |
| Author | Hirabae, Atsuko| Ichihara, Eiki| Sunami, Ryota| Ota, Moeko| Iwamoto, Yoshitaka| Maeda, Yoshinobu| Kiura, Katsuyuki| |
| Abstract | We report a case of late-onset hyperprogressive disease after cessation of a PD-1 inhibitor. A male was diagnosed with metastatic lung adenocarcinoma with little progression for 2 months before treatment. He received pembrolizumab as a second-line treatment and was subsequently prescribed docetaxel for 3 months until a slight increase in pleural effusion. At the time of progression to docetaxel, he commenced prednisolone because of immune-system-related diarrhea. After that, his general condition rapidly worsened with severe fatigue and hypoxia. Computed tomography revealed a massive increase of pleural effusion and replacement of almost the entire liver with cancer over a period of 5 weeks. |
| Keywords | lung cancer immune checkpoint inhibitors pembrolizumab hyperprogression |
| Amo Type | Case Report |
| Published Date | 2020-10 |
| Publication Title | Acta Medica Okayama |
| Volume | volume74 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 423 |
| End Page | 425 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| Copyright Holders | CopyrightⒸ 2020 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 33106698 |
| Web of Science KeyUT | 000581970100007 |
| NAID | 120006892928 |
| FullText URL | J_Thorac_Oncol_201907017.pdf |
|---|---|
| Author | Makimoto, Go| Ohashi, Kadoaki| Tomida, Shuta| Nishii, Kazuya| Matsubara, Takehiro| Kayatani, Hiroe| Higo, Hisao| Ninomiya, Kiichiro| Sato, Akiko| Watanabe, Hiromi| Kano, Hirohisa| Ninomiya, Takashi| Kubo, Toshio| Rai, Kammei| Ichihara, Eiki| Hotta, Katsuyuki| Tabata, Masahiro| Toyooka, Shinichi| Takata, Minoru| Maeda, Yoshinobu| Kiura, Katsuyuki| |
| Keywords | ALK G1202R Alectinib Amphiregulin MET NSCLC |
| Published Date | 2019-07-30 |
| Publication Title | Journal of Thoracic Oncology |
| Volume | volume14 |
| Issue | issue11 |
| Publisher | Elsevier |
| Start Page | 2009 |
| End Page | 2018 |
| ISSN | 15560864 |
| NCID | AA12058455 |
| Content Type | Journal Article |
| language | 英語 |
| OAI-PMH Set | 岡山大学 |
| Copyright Holders | © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved. |
| File Version | author |
| PubMed ID | 31374369 |
| DOI | 10.1016/j.jtho.2019.07.017 |
| Web of Science KeyUT | 000492678300025 |
| Related Url | isVersionOf https://doi.org/10.1016/j.jtho.2019.07.017 |
| FullText URL | fulltext.pdf |
|---|---|
| Author | Katsui, Kuniaki| Ogata, Takeshi| Watanabe, Kenta| Katayama, Norihisa| Kuroda, Masahiro| Kiura, Katsuyuki| Hiraki, Takao| Maeda, Yoshinobu| Toyooka, Shinichi| Kanazawa, Susumu| |
| Keywords | cisplatin docetaxel dose-volume histogram non-small cell lung cancer PACIFIC trial radiation pneumonitis |
| Published Date | 2020-05-04 |
| Publication Title | Cancer Medicine |
| Publisher | Wiley |
| ISSN | 2045-7634 |
| Content Type | Journal Article |
| language | 英語 |
| OAI-PMH Set | 岡山大学 |
| Copyright Holders | © 2020 The Authors. |
| File Version | publisher |
| PubMed ID | 32364685 |
| DOI | 10.1002/cam4.3093 |
| Web of Science KeyUT | 000530411600001 |
| Related Url | isVersionOf https://doi.org/10.1002/cam4.3093 |
| FullText URL | fulltext.pdf |
|---|---|
| Author | Sugimoto, Seiichiro| Soh, Junichi| Suzawa, Ken| Miyoshi, Kentaroh| Otani, Shinji| Yamamoto, Hiromasa| Okazaki, Mikio| Yamane, Masaomi| Oto, Takahiro| Kanazawa, Susumu| Kiura, Katsuyuki| Toyooka, Shinichi| |
| Keywords | Lung cancer Aspergillosis Surgery Radiation Chemotherapy |
| Note | This is a post-peer-review, pre-copyedit version of an article published in Surgery Today. The final authenticated version is available online at: http://dx.doi.org/10.1007/s00595-020-01960-5.| |
| Published Date | 2020-01-21 |
| Publication Title | Surgery Today |
| Volume | volume50 |
| Issue | issue8 |
| Publisher | Springer |
| Start Page | 863 |
| End Page | 871 |
| ISSN | 0941-1291 |
| NCID | AA10824685 |
| Content Type | Journal Article |
| language | 英語 |
| OAI-PMH Set | 岡山大学 |
| File Version | author |
| PubMed ID | 31965262 |
| DOI | 10.1007/s00595-020-01960-5 |
| Web of Science KeyUT | 000550244700010 |
| Related Url | isVersionOf https://doi.org/10.1007/s00595-020-01960-5 |
| JaLCDOI | 10.18926/AMO/55446 |
|---|---|
| FullText URL | 71_5_453.pdf |
| Author | Taniguchi, Akihiko| Miyahara, Nobuaki| Oda, Naohiro| Morichika, Daisuke| Ichihara, Eiki| Oze, Isao| Tanimoto, Yasushi| Ichikawa, Hirohisa| Fujii, Utako| Tanimoto, Mitsune| Kanehiro, Arihiko| Kiura, Katsuyuki| |
| Abstract | Although recent retrospective studies suggested that the use of β-blockers appears to help improve the mortality rate and decrease the rate of exacerbation in chronic obstructive pulmonary disease (COPD) patients with heart failure, the effects of β-blockers on COPD patients without heart failure have not been established. Based on previous reports, we have launched a multicenter, prospective, single-arm phase II study to evaluate the preventive effect of the cardioselective β-blocker bisoprolol in COPD exacerbation, in Japanese individuals with moderate-to-severe COPD who do not have heart failure but do have hypertension requiring the use of medication. The primary endpoint is the rate of mild-to-severe COPD exacerbation. The results of this study will clarify whether bisoprolol can prevent exacerbation in COPD patients without heart failure. |
| Keywords | chronic obstructive pulmonary disease β-blocker bisoprolol exacerbation heart failure |
| Amo Type | Clinical Study Protocol |
| Published Date | 2017-10 |
| Publication Title | Acta Medica Okayama |
| Volume | volume71 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 453 |
| End Page | 457 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| Copyright Holders | CopyrightⒸ 2017 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 29042706 |
| Author | Shien, Kazuhiko| Toyooka, Shinichi| Ichimura, Kouichi| Soh, Junichi| Furukawa, Masashi| Maki, Yuho| Muraoka, Takayuki| Tanaka, Norimitsu| Ueno, Tsuyoshi| Asano, Hiroaki| Tsukuda, Kazunori| Yamane, Masaomi| Oto, Takahiro| Kiura, Katsuyuki| Miyoshi, Shinichiro| |
|---|---|
| Published Date | 2012-07 |
| Publication Title | Lung Cancer |
| Volume | volume77 |
| Issue | issue1 |
| Content Type | Journal Article |
| JaLCDOI | 10.18926/AMO/31310 |
|---|---|
| FullText URL | fulltext.pdf |
| Author | Tamura, Makoto| Ueoka, Hiroshi| Kiura, Katsuyuki| Tabata, Masahiro| Shibayama, Takuo| Miyatake, Kazuyo| Genba, Kenichi| Hiraki, Shunkichi| harada, Mine| |
| Abstract | <p>In order to elucidate factors influencing the prognosis of small-cell lung cancer (SCLC), we reviewed the records of 253 patients with SCLC and evaluated 20 pretreatment prognostic factors by univariate analysis and Cox's multiple regression analysis. Recursive partitioning and amalgamation (RPA) was employed to identify subgroups with similar survival rates. Cox's multiple regression analysis identified five significant factors: extent of disease, number of metastatic sites, serum albumin, serum lactate dehydrogenase, and presence of weight loss. Among these, extent of disease was the most influential factor. RPA analysis revealed three subgroups predicting significantly different prognoses. The median survival time and 3-year survival rate were 18.4 months and 20.6%, respectively for the good-risk group (limited disease without weight loss), 13.5 months and 9.1%, respectively for the intermediate-risk group (limited disease with weight loss or extensive disease with less than two metastatic sites), and 9.2 months and 0%, respectively for the poor-risk group (extensive disease with two or more metastatic sites). These results will be useful for development of new staging system or subsequent stratification for randomized trials.</p> |
| Keywords | prognostic factors Cox's multiple regression analysis recursive partitioning and amalgamayion method small-sell lung canser |
| Amo Type | Article |
| Published Date | 1998-04 |
| Publication Title | Acta Medica Okayama |
| Volume | volume52 |
| Issue | issue2 |
| Publisher | Okayama University Medical School |
| Start Page | 105 |
| End Page | 111 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 9588226 |
| Web of Science KeyUT | 000073363000006 |
| JaLCDOI | 10.18926/AMO/53671 |
|---|---|
| FullText URL | 69_5_261.pdf |
| Author | Nojima, Daisuke| Fujimoto, Nobukazu| Kato, Katsuya| Fuchimoto, Yasuko| Kiura, Katsuyuki| Kishimoto, Takumi| Tanimoto, Mitsune| |
| Abstract | We investigated the clinical features of asbestos-induced diffuse pleural thickening (DPT) with severe respiratory compromise. We conducted a retrospective study of consecutive subjects with asbestos-induced DPT. Medical data such as initial symptoms, radiological findings, respiratory function test results, and clinical course were collected and analyzed. There were 24 patients between 2003 and 2012. All were men, and the median age at the development of DPT was 74 years. The top occupational category associated with asbestos exposure was dockyard workers. The median duration of asbestos exposure was 35.0 years, and the median latency from first exposure to the onset of DPT was 49.0 years. There were no significant differences in respiratory function test results between the higher and lower Brinkman index groups or between unilateral and bilateral DPT. Thirteen patients had a history of benign asbestos pleural effusion (BAPE), and the median duration from pleural fluid accumulation to DPT with severe respiratory compromise was 28.4 months. DPT with severe respiratory compromise can develop after a long latency following occupational asbestos exposure and a history of BAPE. |
| Keywords | asbestos pleural thickening MRC dyspnea scale respiratory function test costophrenic angle |
| Amo Type | Original Article |
| Published Date | 2015-10 |
| Publication Title | Acta Medica Okayama |
| Volume | volume69 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 261 |
| End Page | 266 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| Copyright Holders | CopyrightⒸ 2015 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 26490022 |
| Web of Science KeyUT | 000365519600001 |
| JaLCDOI | 10.18926/AMO/32200 |
|---|---|
| FullText URL | fulltext.pdf |
| Author | Ohnoshi, Taisuke| Hiraki, Shunkichi| Ueda, Nobuo| Fujii, Masafumi| Machida, Ken-ichi| Ueoka, Hiroshi| Kawahara, Shin| Kozuka, Akira| Kiura, Katsuyuki| Moritaka, Tomonori| Kodani, Tsuyoshi| Kamei, Haruhito| Kimura, Ikuro| |
| Abstract | <p>Twenty-seven previously untreated patients with unresectable non-small cell lung cancer were treated with a 3-drug combination of ifosfamide, cisplatin, and vindesine as a phase II study. Patients received ifosfamide, 1.3g/m2, on days 1 to 5; cisplatin, 20mg/m2, on days 1 to 5; and vindesine, 3mg/m2, on days 1 and 8; with a sufficient parenteral hydration. Courses were repeated every 4 weeks. Twenty males and seven females with a median age of 61 years were treated and fully evaluated. Five patients had stage IIIA, seven had stage IIIB, and 15 had stage IV disease. One patient with adenocarcinoma achieved a complete response and 16 achieved a partial response, for an overall response rate of 63% (95% confidence limit: 45% to 81%). The median duration of response was 34 weeks (range: 9 to 52 weeks). The median survival time was 58 weeks for patients with IIIA/B disease, and 33 weeks for those with IV disease. The major toxicity was myelosuppression, however, it was generally well-tolerated. These results indicate that the 3-drug combination is active against non-small cell lung cancer and warrants further clinical trials.</p> |
| Keywords | non-small cell lung cancer ifosfamide cisplatin vindesine |
| Amo Type | Article |
| Published Date | 1991-10 |
| Publication Title | Acta Medica Okayama |
| Volume | volume45 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 357 |
| End Page | 361 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 1661559 |
| Web of Science KeyUT | A1991GN53800010 |
| FullText URL | fulltext.pdf |
|---|---|
| Author | Nishii, Kazuya| Inoue, Masaaki| Obata, Hideto| Ueda, Yutaka| Kozuki, Toshiyuki| Yamasaki, Masahiro| Moritaka, Tomonori| Awaya, Yoshikazu| Sugimoto, Keisuke| Gemba, Kenichi| Kuyama, Shoichi| Ichikawa, Hirohisa| Shibayama, Takuo| Kubota, Tetsuya| Kodani, Masahiro| Kishino, Daizo| Fujimoto, Nobukazu| Ishikawa, Nobuhisa| Tsubata, Yukari| Ishii, Tomoya| Fujitaka, Kazunori| Hotta, Katsuyuki| Kiura, Katsuyuki| |
| Keywords | Database observational study real world data surveillance treatment |
| Published Date | 2021-01-12 |
| Publication Title | Thoracic Cancer |
| Volume | volume12 |
| Issue | issue5 |
| Publisher | Wiley |
| Start Page | 725 |
| End Page | 731 |
| ISSN | 1759-7706 |
| Content Type | Journal Article |
| language | 英語 |
| OAI-PMH Set | 岡山大学 |
| Copyright Holders | © 2020 The Authors. |
| File Version | publisher |
| PubMed ID | 33434415 |
| DOI | 10.1111/1759-7714.13789 |
| Web of Science KeyUT | 000606961500001 |
| Related Url | isVersionOf https://doi.org/10.1111/1759-7714.13789 |
| FullText URL | fulltext.pdf |
|---|---|
| Author | Senoo, Satoru| Miyahara, Nobuaki| Taniguchi, Akihiko| Oda, Naohiro| Itano, Junko| Higo, Hisao| Hara, Naofumi| Watanabe, Hiromi| Kano, Hirohisa| Suwaki, Toshimitsu| Fuchimoto, Yasuko| Kajimoto, Kazuhiro| Ichikawa, Hirohisa| Kudo, Kenichiro| Shibayama, Takuo| Tanimoto, Yasushi| Kuyama, Shoichi| Kanehiro, Arihiko| Maeda, Yoshinobu| Kiura, Katsuyuki| Okayama Respiratory Disease Study Group (ORDSG)| |
| Published Date | 2020-08-27 |
| Publication Title | PLoS ONE |
| Volume | volume15 |
| Issue | issue8 |
| Publisher | Public Library of Science |
| Start Page | e0236935 |
| ISSN | 1932-6203 |
| Content Type | Journal Article |
| language | 英語 |
| OAI-PMH Set | 岡山大学 |
| Copyright Holders | © 2020 Senoo et al. |
| File Version | publisher |
| PubMed ID | 32853277 |
| DOI | 10.1371/journal.pone.0236935 |
| Web of Science KeyUT | 000566948800009 |
| Related Url | isVersionOf https://doi.org/10.1371/journal.pone.0236935 |
| JaLCDOI | 10.18926/AMO/31591 |
|---|---|
| FullText URL | fulltext.pdf |
| Author | Ohnoshi, Taisuke| Hiraki, Shunkichi| Fujii, Masafumi| Ueoka, Hiroshi| Yonei, Toshiro| Tamura, Makoto| Moritaka, Tomonori| Mima, Yuchi| Horiguchi, Takashi| Kiura, Katsuyuki| Kamei, Haruhito| Kodani, Tsuyoshi| Hiraki, Yoshio| Kimura, Ikuro| |
| Abstract | <p>We evaluated the long-term outcome of 148 patients with small cell lung cancer (SCLC) who had been entered into clinical trials of chemotherapy with or without thoracic and prophylactic cranial irradiation (PCI) between 1981 and 1987. Eighteen patients (12%) survived for 2 or more years. With a minimum follow-up of 4.5 years, 10 of the 18 patients who remained disease-free at 2 years are currently alive and free of SCLC. Seven of these 10 patients currently function as they did before diagnosis. However, three suffer from central nervous system changes of varying degrees in severity which appeared 2-3 years after PCI. Eight of the 18 patients who were disease-free at 2 years have died. Two died of isolated relapse in the brain at 3.6 and 4.2 years after initiation of chemotherapy. Five died of other malignancies while continuing their complete response to SCLC; two of non-small cell lung cancer, two of acute myelogenous leukemia, and one of hepatocellular carcinoma. Another patient died of an unrelated disease without any evidence of SCLC. A small but substantial proportion of patients who underwent intensive treatment will achieve long-term survival; however, these patients remain at higher risk for second cancers and late toxicities. Therefore, attention must be directed to defining the safest way to employ such treatment in the management of SCLC.</p> |
| Keywords | small cell lung cancer long-term survivors late relapse toxicities complications |
| Amo Type | Article |
| Published Date | 1993-06 |
| Publication Title | Acta Medica Okayama |
| Volume | volume47 |
| Issue | issue3 |
| Publisher | Okayama University Medical School |
| Start Page | 209 |
| End Page | 214 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 8397470 |
| Web of Science KeyUT | A1993LL12400010 |
| FullText URL | fulltext.pdf |
|---|---|
| Author | Okawa, Sachi| Rai, Kammei| Fujii, Nobuharu| Gion, Yuka| Ninomiya, Kiichiro| Kato, Yuka| Taniguchi, Akihiko| Kubo, Toshio| Ichihara, Eiki| Ohashi, Kadoaki| Miyahara, Nobuaki| Hotta, Katsuyuki| Tabata, Masahiro| Maeda, Yoshinobu| Kiura, Katsuyuki| |
| Keywords | EGFR IgG4-related disease marginal zone lymphoma osimertinib |
| Published Date | 2021-09-01 |
| Publication Title | Internal Medicine |
| Volume | volume60 |
| Issue | issue17 |
| Publisher | The Japanese Society of Internal Medicine |
| Start Page | 2831 |
| End Page | 2837 |
| ISSN | 0918-2918 |
| NCID | AA10827774 |
| Content Type | Journal Article |
| language | 英語 |
| OAI-PMH Set | 岡山大学 |
| Copyright Holders | © 2021 The Japanese Society of Internal Medicine |
| File Version | publisher |
| PubMed ID | 33775999 |
| DOI | 10.2169/internalmedicine.6470-20 |
| Web of Science KeyUT | 000695856000020 |
| Related Url | isVersionOf https://doi.org/10.2169/internalmedicine.6470-20 |
| FullText URL | fulltext.pdf |
|---|---|
| Author | Ichihara, Eiki| Miyahara, Nobuaki| Maeda, Yoshinobu| Kiura, Katsuyuki| |
| Keywords | lung cancer interstitial pneumonia |
| Published Date | 2020-01-15 |
| Publication Title | Internal Medicine |
| Volume | volume59 |
| Issue | issue2 |
| Publisher | 日本内科学会 |
| Start Page | 163 |
| End Page | 167 |
| ISSN | 0918-2918 |
| NCID | AA10827774 |
| Content Type | Journal Article |
| language | 英語 |
| Copyright Holders | © 2020 by The Japanese Society of Internal Medicine |
| File Version | publisher |
| PubMed ID | 31534086 |
| NAID | 130007785095 |
| DOI | 10.2169/internalmedicine.3481-19 |
| Web of Science KeyUT | 000507577600002 |
| Related Url | isVersionOf https://doi.org/10.2169/internalmedicine.3481-19 |
| JaLCDOI | 10.18926/AMO/31553 |
|---|---|
| FullText URL | fulltext.pdf |
| Author | Tabata, Masahiro| Ohnoshi, Taisuke| Ueoka, Hiroshi| Kiura, Katsuyuki| Kimura, Ikuro| |
| Abstract | <p>We report a preliminary study to determine whether MDR1 gene expression level in small cell lung cancer (SCLC) tumors is a useful predictor of tumor response to chemotherapy and patient survival in association with myc amplification in the tumor. We analyzed 18 patients with SCLC receiving adriamycin and etoposide combination chemotherapy between August 1989 and November 1991; 16 males and 2 females, median age of 68 years, and 7 with limited disease and 11 with extensive disease. MDR1 mRNA expression level and myc family gene amplification were simultaneously determined by polymerase chain reaction using transbronchial biopsy specimens which were obtained at diagnosis. Patients with tumors expressing low MDR1 mRNA responded more favorably to chemotherapy than those with tumors expressing high MDRI mRNA, however, the difference in tumor response was statistically not significant (84.6% versus 40%). The overall survival was significantly shorter in the latter than in the former (7.2 months versus 11.7 months; p = 0.023). The survival of the 4 patients with tumor showing myc family gene amplification was almost identical to that of patients with tumors showing no amplification of the gene (8.2 months versus 8.8 months; p = 0.73). Multivariate Cox's regression analysis supports the notion that MDR1 may be a useful independent prognostic factor.</p> |
| Keywords | small cell lung cancer MDR1 mRNA expression myc gene amplification prognostic factor |
| Amo Type | Article |
| Published Date | 1993-08 |
| Publication Title | Acta Medica Okayama |
| Volume | volume47 |
| Issue | issue4 |
| Publisher | Okayama University Medical School |
| Start Page | 243 |
| End Page | 248 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | 英語 |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 8213218 |
| Web of Science KeyUT | A1993LV73800004 |
